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Summary
Objective: To quantify the urinary concentration of cartilage oligomeric matrix protein (COMP), and to evaluate the relationship between
urinary COMP concentration and the catabolic activity of synovial ﬂuid (SF) in diseased horses.
Methods: COMP in horse urine was detected by immunoblotting with a monoclonal antibody (mAb; 14G4) raised against equine COMP from
articular cartilage. Urine and serum samples were obtained from 83 Thoroughbred horses with aseptic joint diseases (AJD, 79 horses) or sep-
tic joint diseases (SJD, four horses) at the time of anesthesia induction, and samples of SF were obtained during surgery. Control samples of
urine (n¼ 111) were collected from normal horses free of any orthopedic diseases after they had been racing. COMP concentration was de-
termined in all samples using inhibition enzyme-linked immunosorbent assay (ELISA) with mAb 14G4. SF samples were also used for the
quantiﬁcation of gelatinase activity.
Results: Positive bands of COMP fragments were determined on the immunoblots with mAb 14G4. The urinary COMP concentrations in AJD
and SJD horses (1.02 0.75 and 1.55 1.17 mg/100 mg creatinine, respectively) were signiﬁcantly higher than normal (0.57 0.29 mg/
100 mg creatinine). In 55 horses with fractures in the AJD group there was a logarithmic relationship (r¼0.45, P< 0.001) between the
urinary and SF COMP measurements, while the urinary COMP level was positively correlated with matrix metalloproteinase (MMP)-2 and -9
activities (r¼ 0.30, P< 0.05 and r¼ 0.51, P< 0.001, respectively) in SF.
Conclusions: The urinary COMP assay with mAb 14G4 is useful for discriminating horses with osteoarthritis. The higher COMP levels in urine
from such horses would be indicative of enhanced proteolytic activity, in addition to the increased COMP levels in the diseased joints.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Cartilage oligomeric matrix protein (COMP) in synovial ﬂuid
(SF) and serum has been universally recognized as a sensi-
tive marker of cartilage degradation in clinical studies of
osteoarthritis (OA) and rheumatoid arthritis (RA)1. The
COMP level in SF correlates positively with antigenic kera-
tan sulfate, and also changes depending on differences in
cartilage deterioration in idiopathic osteonecrosis as well
as hip OA2. Also, the serum level of COMP has been
reported to be higher in patients with OA than in healthy
volunteers3. The serum level of COMP is signiﬁcantly corre-
lated with the Western Ontario and McMaster Universities
index pain scale for the lower limbs, and higher in patients
with bilateral knee OA than in unilaterally affected patients4.
Another study has suggested that serum COMP concentra-
tion at the baseline could be useful for predicting the course
of OA, progressors showing higher average values than
non-progressors5. As just above, so far, the serum COMP
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Received 9 February 2006; revision accepted 22 April 2006.11level could be well indicative of the changeable pathology
in human OA, whereas no report has demonstrated whether
the higher serum COMP represents the increased COMP
molecules in diseased SF or not.
In horses with OA, we have demonstrated augmented
degradation of COMP in SF6,7, and suggested that
COMP fragmentation in SF could be useful for monitoring
equine OA in combination with enzyme-linked immuno-
sorbent assay (ELISA) measurements7. Thereafter, we
investigated the clinical usefulness of the serum baseline
COMP level as a diagnostic marker of OA in racehorses;
however, we did not obtain any clear-cut evidence such
as a signiﬁcant correlation of the COMP level in serum
to that in SF, as well as to joint pathology or prognosis.
There may be certain reasons why serum COMP may
be a less sensitive indicator of joint deterioration in
equine OA. Exercise-induced up-regulation of COMP turn-
over might be one factor that would complicate the detec-
tion of changes in serum COMP concentration due to OA
pathology in horses. Neidhart et al.8 pointed out that the
baseline level of COMP in human marathon runners (be-
fore exercise) was signiﬁcantly higher than in non-running
healthy volunteers (controls who had never run in any
competitive race, and who were age- and sex-matched).74
1175Osteoarthritis and Cartilage Vol. 14, No. 11We have also obtained evidence that the baseline level of
COMP in the serum of Thoroughbreds can increase sig-
niﬁcantly as a result of more intensive workouts (unpub-
lished data). Our ﬁnding that the serum COMP level
was increased 1 h after strenuous exercise on a race-
course and then recovered to the baseline within 24 h
is also in agreement with previous studies8,9. The rapid
clearance of COMP from serum might also make it difﬁ-
cult to determine any increase in the serum level speciﬁc
to joint diseases.
Attenuation of COMP outﬂow from joint ﬂuid into the
blood circulation might be another factor that would obscure
any change in the serum COMP concentration due to OA
pathology. In horses with OA, increased catabolic activity
reﬂected in the levels of matrix metalloproteinases
(MMPs) and inﬂammatory cytokines has been demon-
strated in SF10, but so far not in serum. Thus, the attenua-
tion of COMP outﬂow from affected joints might not be due
to proteolytic degradation in the blood compartment. We
have another hypothesis that the increased amount of
COMP fragments released from affected joints could be at-
tenuated principally through dilution with a large volume of
blood, and so would not be detectable unless a blood con-
centrate was examined. If it was possible to quantify COMP
using samples of urine, which is a concentrated ﬁltrate of
blood, then measurements might be correlated with
changes in COMP turnover in response to joint pathology.
The urinary level of C-terminal cross-linking telopeptide of
type II collagen (U-CTX-II) determined using a monoclonal
antibody (mAb) raised against a less-proteolytic linear
amino acid peptide has been demonstrated to be the
most reliable of several biomarkers of OA11. Conveniently,
mAb 14G4, which we previously raised against equine car-
tilage COMP, can recognize the COMP fragments in horse
urine7. Hypothesizing that urinary COMP would be a more
reliable marker of equine OA than serum COMP, we de-
vised a system for assay of urinary COMP using mAb
14G4. The aims of this study were to evaluate the useful-
ness of urinary COMP measurement for discriminating
horses with OA from normal horses, and the relationship
between the level of urinary COMP and joint pathology in
OA assessed by sampling of SF.
Subjects, materials and methods
SAMPLE COLLECTION
Individual urine and serum samples were obtained from
83 Thoroughbred horses with aseptic or septic joint dis-
eases (AJD and SJD, 79 and four horses, respectively)
at the time of anesthesia induction, and samples of SF
were obtained at the time of arthroscopic surgery. All the
horses were determined to be free of any medical dis-
eases including renal failure and uropathy, based on the
preoperative assessment of blood and urine. The surgical
cases of AJD comprised 55 cases of intra-articular fracture
including secondary degenerative joint disease (DJD) and
24 cases of osteochondrosis (OC; including osteocho-
ndritis dissecans (OCD) and bone cyst). Control samples
of urine (n¼ 111) were collected from normal horses
judged to be free of any orthopedic diseases on the basis
of clinical, radiological and ultrasound examinations, after
the horses had won a race. The laboratory tests for the
urine samples also showed no abnormalities suggesting
any renal disorder. The samples were centrifuged to re-
move debris or cells, and the supernatants were stored
at 70(C until assay. Prior to assay, all SF sampleswere pretreated with hyaluronidase according to Neidhart
et al.12 (characteristics of the horses are summarized in
Table I).
ELECTROPHORESIS AND IMMUNOBLOTTING OF URINE
SAMPLES
Following sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis on 15% polyacrylamide gel containing
8 M urea as reported previously13, the gels were electro-
transferred onto polyvinyl diﬂuoride membranes. After
blocking, mAb 14G4, diluted 1:10,000 in 5% skimmed
milk in Tris-buffered saline containing 0.05% Tween 20
(TBS/Tween), was applied to the membrane. Positive bind-
ing to COMP was detected using alkaline phosphatase
(AP)-conjugated goat anti-mouse IgG antibody (A36882) di-
luted 1:10,000 in 2% skimmed milk in TBS/Tween, and
demonstrated by development of the reaction with a sub-
strate (BCIP/NBT, Sigma Fast/B-56552).
INHIBITION ELISA
COMP concentration in urine, SF, and serum was ana-
lyzed by inhibition ELISA with mAb 14G4 directed against
equine COMP designed according to previous protocols6,7
with some modiﬁcations. In brief, 50 ml of puriﬁed horse
COMP antigen in a coating buffer (20 mM sodium carbon-
ate, 20 mM sodium bicarbonate, 0.002% sodium azide, pH
10) was placed in each well at 5 mg/ml, and then incubated
for 2 h at room temperature followed by overnight at 4(C.
Seventy microliters of diluted standards (range: 13.5e
0.01 mg/ml) and the samples (ﬁnal dilutions: urine 1/5, SF
1/70, serum 1/20) were mixed with the same volume of
mAb 14G4 (ﬁnal dilution: 1/100,000) in phosphate-
buffered saline containing 0.05% Tween 20 (PBS/Tween),
Table I
Characteristics of the horses, and diagnosis of the affected joints
Normal horses (n¼ 111)
Age (years, mean 1 SD) 2.5 1.1
Gender
Male 71
Female 40
Joint diseased horses (n¼ 83)
Age (years, mean 1SD) 2.2 1.2
Gender
Male 52
Female 37
AJD (n¼ 79)
Fracture
Carpus 37
Hind fetlock 14
Fore fetlock 3
Tarsus 1
OC
Tarsus 19
Stiﬂe 5
SJD (n¼ 4)
Shoulder 1
Fore fetlock 1
Hind fetlock 1
Tarsus 1
The control samples were obtained from the normal horses
without any joint diseases. Diseased samples were divided into
two categories such as AJD and SJD.
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washed with PBS, blocked, and then incubated with
100 ml/well of the COMP-antibody mixture for 1 h at 37(C
and then for 1 h at 4(C. Binding of the primary antibody
to COMP on the plate was detected using goat
anti-mouse IgG conjugated to AP and addition of an AP
chromophore. One hour later, production of the chromo-
phore was stopped by addition of 2 M H2CO3 (30 ml/well),
and the absorbance was read at 405 nm (OD405). To
determine the intra- and inter-assay variability, we thawed
fresh aliquots of a urine sample and measured 10 repeats
on one plate for 10 consecutive working days (10 plates).
Considering that more concentrated urine would show
a higher COMP level, measurements of urinary COMP
(mg/ml) were normalized to the urinary creatinine concen-
tration (mg/dl), which was quantiﬁed by the Jaffe method
(Creatinine Test Wako, 277-10501), and expressed as mg
COMP/100 mg creatinine.
ANALYSIS OF SF GELATINASE ACTIVITY
Gelatin zymography was performed using a protocol de-
scribed previously14 with some modiﬁcations. Two microli-
ters of gelatinase standard [supernatant of medium used
for culture of LPS-stimulated equine peripheral blood mono-
nuclear cells (PBMC)] and 1.5 ml of SF were added to 20 ml
of zymography sample buffer containing 7.5% SDS, 2.5%
glycerol, 1% bromophenol blue, and 1 M TriseHCl (pH
6.8). Then 10 ml of the mixture was poured into each well
of a 7.5% polyacrylamide gel containing 2.5 mg/ml gelatin,
followed by electrophoresis at room temperature. The gel
was placed in 2.5% Triton X-100, dissolved in distilled water
for 1 h in order to remove the SDS, and then rinsed repeat-
edly in distilled water to remove the Triton. The gelatinolytic
reaction was allowed to proceed at 37(C for 18 h in the gel-
atin refolding buffer including 50 mM TriseHCl, pH 7.6,
0.2 M NaCl, and 50 mM CaCl2. After staining the gels with
1% Coomassie brilliant blue for 30 min and immersion in
distilled water overnight, gelatinases were visible in the
gels as ﬁne decolorized bands on a blue background. A
mixture of gelatinase standard from a LPS-stimulated
PBMC culture was loaded into one well per plate as the in-
ternal standard for the gelatinase activity.
The enzyme activity of the samples was quantiﬁed as the
band density of pro- and active MMP-2 and -9 in each lane,
which was determined on the basis of molecular size, using
the software packages Image Gauge Ver. 4.0 and L Pro-
cess (Science Lab. 2001, Fuji Film, Tokyo, Japan). The
actual measurements for the samples were converted to
values relative to the internal gelatinase standard.
STATISTICS
All quantitative group data obtained by ELISA were an-
alyzed for normality, and expressed as mean 1 stan-
dard deviation (SD). As the data showed a normal
distribution, we selected the parametric means by statisti-
cal analysis. The differences in urinary COMP concentra-
tions between the groups (vs control) were analyzed by
factorial analysis of variance (ANOVA), and Scheffe´’s
method was used for simultaneous multiple comparisons.
Differences at P< 0.01 were considered statistically sig-
niﬁcant. Relationships of COMP measurements among
the urine, SF, and serum samples from diseased horses,
and the correlation between urinary COMP and MMP ac-
tivity in SF were analyzed using the linear regressionmodel. Correlations were considered statistically signiﬁ-
cant at P< 0.05.
Results
As shown in the immunoblots using the AP reaction
(Fig. 1), mAb 14G4 bound to the fragments of equine
COMP molecules in urine. The sizes of the positive bands
were determined to be approximately 150, 100, and
60 kDa. The urine inhibition curves are given in Fig. 2.
The linear portion of the inhibition curve obtained by diluting
the horse urine (dilution ratio between 0.5 and 0.03125)
paralleled that of the standard curve for puriﬁed COMP
(between 0.8 and 6.75 mg of equine cartilage COMP/ml) us-
ing mAb 14G4. As in urine samples from other species such
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Fig. 1. Immunoblot analysis of urine using mAb 14G4 and AP reac-
tion; mAb 14G4 bound to fragments of equine COMP in urine. The
sizes of the positive bands were determined to be approximately
150, 100, and 60 kDa.
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Fig. 2. Inhibition curves of COMP in urine. The linear portion of the
curve obtained by dilution of horse urine (dilution ratio between 0.5
and 0.03125) paralleled that of the standard curve obtained using
puriﬁed COMP (between 0.8 and 6.75 mg of equine cartilage
COMP/ml) and mAb 14G4.
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Fig. 3. COMP concentration in urine from control and diseased
horses. Urinary COMP levels in horses with AJD (including frac-
tures and OC) and SJD were signiﬁcantly higher than those in
the controls.as mouse, rat, dog, and human, the inhibition curves were
evident for equine articular COMP, although the linear por-
tions for the other species differed slightly in parallel with
that for horse urine. The intra- and inter-assay variabilities
of horse urinary COMP measurements were calculated to
be 6.0 and 8.0%, respectively.
The measured levels of COMP in urine from horses with
AJD (1.02 0.75 mg/100 mg creatinine) and SJD (1.55
1.17 mg/100 mg creatinine) were signiﬁcantly (P< 0.001
and P< 0.01, respectively) higher than those in normal
horses (0.57 0.29 mg/100 mg creatinine) (Fig. 3). The
levels of urinary COMP in horses with fractures (1.01 0.70
mg/100 mg creatinine) and OC (1.04 0.87 mg/100 mg
creatinine) were also signiﬁcantly (P< 0.001 and P< 0.01,
respectively) higher than those in the controls.
The relationships of COMP measurements among the
urine and SF samples are shown in Fig. 4. The relationship
between urinary and SF COMP levels in the 55 horses with
fractures in the AJD group was expressed by a negative log-
arithmic function (r¼0.45, P< 0.001), but there was no
signiﬁcant correlation in the OC and SJD cases. Urinary
COMP level was also not signiﬁcantly correlated with the
serum levels of COMP in any cases of AJD and SJD
(data not shown). In cases of fracture, the urinary COMP
levels were positively correlated with MMP-2 and -9 activity
(r¼ 0.30, P< 0.05 and r¼ 0.51, P< 0.001, respectively) in
SF (Fig. 5).
Discussion
The mAb 14G4, which was raised against monomeric
COMP from equine articular cartilage, recognizes a speciﬁc
peptide sequence, C134FPRVRCINTSPGF147, in the EGF-
like repeat portion of the molecule7. Since positive binding
with mAb 14G4 was well conserved in spite of the increased
fragmentation of COMP in osteoarthritic SF, the epitope
appears to be relatively undamaged during the proteolysis
that occurs in OA. The resistance of the epitope recognized
by mAb 14G4 to COMP catabolism might account for the
detectability of the fragments in urine. Our immunoblots of
equine urine revealed positive bands of approximately
150, 100, and 60 kDa. This molecular size, which wasFracture
y = -3.04 Ln(x) + 6.80
r = 0.45 (n=55, p<0.001)
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Fig. 4. Relationship of measured COMP levels among urine, SF, and serum samples from diseased horses. There was a signiﬁcant negative
logarithmic correlation between the urinary and SF COMP levels in horses with fracture, but no signiﬁcant correlation between OC and SJD
cases.
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Fig. 5. Correlation of urinary COMP levels with MMP-2 and -9 activities in SF from horses with fracture. The urinary COMP levels were
positively correlated with MMP-2 and -9 activities.larger than we expected, was approximately similar to that
of the bands representing degradation products in SF we
reported previously7. In OA patients it has been reported
that most of the MMPs that play a critical role in joint
destruction show evidently higher proteolytic activity in
SF, while not so high in serum, unlike the situation in
RA15,16. COMP molecules released from the extra cellular
matrix (ECM) could be fragmented enzymatically in the
SF, whereas the fragments ﬂowing out of the SF might be
degraded to a lesser extent during blood circulation. Al-
though at present we have no explanation for how large
COMP fragments can be transferred through the glomerular
basement membrane, COMP fragments might be degraded
to a lesser extent during ﬁltration from the blood compart-
ment into urine.
The linear portions of inhibition curves for not only equine
urine but also samples from other species such as mouse,
rat, dog, and human, contained portions that paralleled the
standard curve obtained using puriﬁed COMP. In prelimi-
nary studies (data not shown), we investigated whether
any other factors such as circadian rhythm, exercise, and
diuretics might compromise the reproducibility of urinary
COMP data. Although we found no evidence of any effect
of circadian rhythm on the measurements, the urine level
of COMP in the afternoon was slightly higher than that in
the morning (not signiﬁcant difference). In addition, urine
samples taken within 30 min after strenuous exercise
showed a slightly higher concentration of COMP, which
was also not signiﬁcantly different from that before exercise.
The large variance of the urine levels in our normal horses,
as the percentage of SD divided by the mean value in the
controls is 51%, could be partially due to the circadian
rhythm. In rat urine obtained at the same time of a day,
the SD is lower, that is around 10% of the average of the
COMP baseline. Urinary COMP became undetectable in
samples taken after diuresis with furosemide. We obtained
the control samples from horses on one day, and intrave-
nously administered 80 mg furosemide to them just around
the same time of the next day. The urine samples were ob-
tained on urination after a few minutes of the injection, and
analyzed by immunoblotting and ELISA. The positive bands
of COMP seen in the control samples disappeared in the
sample after the furosemide injection. Identically, the urine
COMP level after the injection fell below measurable limits
of the inhibition ELISA. On the basis of the inhibition curve
for the equine cartilage COMP standard, the urinary COMP
levels for horses with AJD and SJD were signiﬁcantly higher
than those for normal horses. Nevertheless, the increasedurine COMP levels in the diseased horses were not posi-
tively correlated with the levels in either their SF or serum.
Taken as a whole, the statistical analysis demonstrated
that the higher COMP level in urine might not simply reﬂect
the increase of COMP in diseased joints, even though
COMP accumulation has been demonstrated around carti-
lage lesions and sites showing mild ﬁbrillation, severe ﬁbril-
lation and ﬁbrocartilage17.
In the 55 horses with fracture in the AJD group, the neg-
ative logarithmic relationship between the urinary and SF
levels of COMP suggested further possibilities about the
clinical signiﬁcance of urinary COMP as a biomarker. Based
on the dispersal of sample values in the scattergram
(Fig. 4), it appeared that cases could be sorted approxi-
mately into three groups: (1) a high SF COMP level with
a low urinary COMP level, (2) a high urinary COMP level
with low SF COMP level, and (3) a group that lay outside
the other two groups. This might correspond to three stages
in joint pathology secondary to intra-articular fracture: an
acute phase during which mechanical injury of the bone
and cartilage is limited to the area adjacent to the fracture
site, a chronic phase (or OA phase) during which moderate
to severe cartilage degradation and bone remodeling
(deformity) could expand around the wound, and a transi-
tional phase in which the OA (or DJD) pathology would be
mild. It has been reported previously that MMP activity in
SF increases in relation to the severity of cartilage damage
in equine osteoarthritic joints18,19. As the signiﬁcant
increase of MMP-9 monomer and dimer in the SF could
be indicative of severe cartilage alteration in OCD as well
as DJD18, we evaluated the correlation of urinary COMP
measurements with MMP-2 and -9 activities in SF. As
expected, the urinary COMP level was signiﬁcantly corre-
lated with the activities of MMP-2 and -9 in SF, especially
the latter. COMP macromolecules originating from injured
or degenerative ECM would be enzymatically fragmented
in SF prior to lymphatic/blood outﬂow, while subsequently
the fragments would not be degraded any more in blood
circulation, and ﬁltered and concentrated into urine. Thus
the catabolic activity in the SF of horses with OA would
be predictable by analysis of urinary COMP.
Again, considering the characteristic correlation be-
tween measured COMP levels in SF and urine in horses
with fracture, with reference to enhanced enzymatic deg-
radation rather than overproduction (or accumulation) of
COMP during the development of OA, the partitioning of
the data into the three groups mentioned above could
be explained as follows. A lower urinary COMP level
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amount of COMP would be degraded to a lesser extent
and increasingly retained (the cases represented in the
ﬁrst group on the scattergram). On the other hand, in
the cases with a high level of urinary COMP, strong cat-
abolic activity in SF would reduce the molecular size of
COMP, and the resulting fragments would easily ﬂow
out into the synovial lymphatic system (the cases repre-
sented in the second group of the scattergram). The tran-
sitional cases might be those distributed in the
intermediate part of the scattergram. It has been reported
that increased MMP-9 activity may be associated with the
severity of cartilage deterioration in OCD18, and another
study of OC lesions has demonstrated an increase of cat-
abolic enzymes and lower regeneration of matrix mole-
cules in response to mechanical forces20. In the present
study there was no signiﬁcant correlation between urinary
COMP levels and SF gelatinase activity in OC cases.
Although the COMP levels in urine and SF from OC
cases were equivalent to those of fracture cases, the ge-
latinase levels in SF from OC horses were lower than the
fracture cases (Table II, Fig. 3). It has been reported that
the MMP-2 and -9 can be overgenerated by chondrocytes
at the OCD lesions21. The MMP-2 and -9 activities could
be more increased at the OC lesions of cartilage rather
than in the SFs. We speculate in our OC cases that the
COMP molecules could be principally degenerated by
the gelatinase increasing at the OC lesions in cartilage,
therefore that the increased urine level of COMP fragments
might correlate to the increased gelatinase activity in OC
cartilage rather than that in the SF. Re-evaluation should
be also done using a larger number of OC samples.
This study represents the ﬁrst attempt to quantify the con-
centration of COMP in urine, and is the ﬁrst to demonstrate
increased urinary COMP levels in horses with AJD and
SJD. Assay of urinary COMP using mAb 14G4 is useful
for discriminating horses with OA. The higher COMP levels
in urine from horses with OA are indicative of augmented
proteolytic activity, in addition to increased COMP levels
in the diseased joints themselves.
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